The Importance of MTHFD2 Expression in Renal Cell Carcinoma

Year 2025, Volume: 20 Issue: 3, 121 - 129, 20.10.2025

Onur Ceylan , Remzi Arslan

https://doi.org/10.33719/nju1594236

Abstract

Project Number

TAB-2021-8842

The Importance of MTHFD2 Expression in Renal Cell Carcinoma

Abstract

Objective: Renal cell carcinoma (RCC) carries a poor prognosis at advanced stages. Identifying reliable prognostic biomarkers is essential for improved clinical management. Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2), a key mitochondrial enzyme in the folate cycle, is overexpressed in various rapidly proliferating malignancies. However, its prognostic value in RCC remains underexplored. For this reason, we purposed to search the prognostic role of MTHFD2 expression in RCC.
Materials and Methods: This study included 124 RCC patients who applied radical nephrectomy between 2015 and 2020. Immunohistochemical analysis of MTHFD2 expression was performed on paraffin-embedded tumor samples. Expression levels were classified using a histoscore-based system: low (grades 0–1) and high (grades 2–3). Correlations between MTHFD2 expression and clinical/pathological parameters were evaluated, and survival analysis was conducted.
Results: MTHFD2 overexpression was detected in 53% of tumors and was absent in adjacent non-tumor tissues. High expression was significantly associated with adverse prognostic features, including higher histological grade, sarcomatoid differentiation, advanced pT stage, and presence of distant metastases (all p < 0.05). Patients with high MTHFD2 expression had significantly reduced overall survival (p < 0.001). Remarkably, early-stage tumors (pT1–2) with high MTHFD2 expression were linked to shorter survival compared to more advanced tumors (pT3–4) with low expression.
Conclusion: Our results pointed out that high expression of MTHFD2 is associated with poor prognosis in RCC and may function as an independent prognostic biomarker. These findings underscore the potential of MTHFD2 in risk stratification and as a therapeutic target in RCC.

Keywords

MTHFD2 , renal cell carcinoma , prognostic marker , immunohistochemical study

Ethical Statement

This study was approved by Ethics Committee of Atatürk University (Approval number: B.30.2.ATA.0.01.00/388, Date: 26.06.2020).

Supporting Institution

Our study was supported by Atatürk University Scientific Research Project Coordination Unit (Project Code: TAB-2021-8842).

Project Number

TAB-2021-8842

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442
• Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–24. https://doi.org/10.1016/j.eururo.2015.01.005
• Noone A, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al. SEER cancer statistics review, 1975–2015. Bethesda (MD): National Cancer Institute; 2018. Available from: https://seer.cancer.gov/csr/1975_2015/
• Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376(4):354–66. https://doi.org/10.1056/NEJMra1601333
• Newman AC, Maddocks ODK. One-carbon metabolism in cancer. Br J Cancer. 2017;116(12):1499–504. https://doi.org/10.1038/bjc.2017.118
• Nilsson R, Jain M, Madhusudhan N, Sheppard NG, Strittmatter L, Kampf C, et al. Metabolic enzyme expression highlights a key role for MTHFD2 and the mitochondrial folate pathway in cancer. Nat Commun. 2014;5:3128. https://doi.org/10.1038/ncomms4128
• Shin M, Bryant JD, Momb J, Appling DR. Mitochondrial MTHFD2L is a dual redox cofactor-specific methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase expressed in both adult and embryonic tissues. J Biol Chem. 2014;289(22):15507–17. https://doi.org/10.1074/jbc.M114.555573
• Nilsson R, Nicolaidou V, Koufaris C. Mitochondrial MTHFD isozymes display distinct expression, regulation, and association with cancer. Gene. 2019;716:144032. https://doi.org/10.1016/j.gene.2019.144032
• He Z, Wang X, Zhang H, Liang B, Zhang J, Zhang Z, et al. High expression of folate cycle enzyme MTHFD1L correlates with poor prognosis and increased proliferation and migration in colorectal cancer. J Cancer. 2020;11(14):4213–21. https://doi.org/10.7150/jca.35014
• Liu F, Liu Y, He C, Tao L, He X, Song H, et al. Increased MTHFD2 expression is associated with poor prognosis in breast cancer. Tumour Biol. 2014;35(9):8685–90. https://doi.org/10.1007/s13277-014-2144-2
• Green NH, Galvan DL, Badal SS, Chang BH, LeBleu VS, Long J, et al. MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma. Oncogene. 2019;38(34):6211–25. https://doi.org/10.1038/s41388-019-0869-4
• Lee D, Xu IM, Chiu DK, Lai RK, Tse AP, Li LL, et al. Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma. J Clin Invest. 2017;127(5):1856–72. https://doi.org/10.1172/JCI91015
• Compérat EM, Burger M, Gontero P, Mostafid AH, Palou J, Rouprêt M, et al. Grading of urothelial carcinoma and the new WHO classification of tumours of the urinary system and male genital organs 2016. Eur Urol Focus. 2019;5(3):457–66. https://doi.org/10.1016/j.euf.2018.01.009
• Lin H, Huang B, Wang H, Liu X, Hong Y, Qiu S, et al. MTHFD2 overexpression predicts poor prognosis in renal cell carcinoma and is associated with cell proliferation and vimentin-modulated migration and invasion. Cell Physiol Biochem. 2018;51(2):991–1000. https://doi.org/10.1159/000495380
• Silva RV, Berzotti LA, Laia MG, Araújo LS, Silva CA, Ribeiro R, et al. Implications of MTHFD2 expression in renal cell carcinoma aggressiveness. PLoS One. 2024;19(2):e0299353. https://doi.org/10.1371/journal.pone.0299353
• Ju H-Q, Lu Y-X, Chen D-L, Zuo Z-X, Liu Z-X, Wu Q-N, et al. Modulation of redox homeostasis by inhibition of MTHFD2 in colorectal cancer: mechanisms and therapeutic implications. JNCI J Natl Cancer Inst. 2019;111(6):584–96. https://doi.org/10.1093/jnci/djy161
• Miyo M, Konno M, Colvin H, Nishida N, Koseki J, Kawamoto K, et al. The importance of mitochondrial folate enzymes in human colorectal cancer. Oncol Rep. 2017;37(1):417–25. https://doi.org/10.3892/or.2016.5289
• Liu X, Huang Y, Jiang C, Ou H, Guo B, Liao H, et al. Methylenetetrahydrofolate dehydrogenase 2 overexpression is associated with tumor aggressiveness and poor prognosis in hepatocellular carcinoma. Dig Liver Dis. 2016;48(8):953–60. https://doi.org/10.1016/j.dld.2016.03.022